For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.

Key

Inclusion Criteria:

- Subjects ≥ 18 years of age

- Chronic myeloid leukemia (CML) in chronic or advanced phase (including Ph+ALL) with
progression/failure during or suboptimal response to imatinib, nilotinib or dasatinib
(see protocol for details)

- Performance Status 0-1 with resolution of toxicity from prior therapy

Key Exclusion Criteria:

- Known Abl-kinase T315I or T315A mutation

- Laboratory abnormalities:

- Uncorrected serum calcium or phosphate below institutional LLN

- Amylase or lipase Grade ≥1

- Blood count values Grade ≥3

- Serious or uncontrolled medical disorder (including infection or cardiovascular
disease) or dementia or other serious psychiatric condition

- Women who are pregnant or breastfeeding or WOCBP who are unwilling or unable to use
an acceptable method to avoid pregnancy during the entire study period

- Must be ≥6 months after stem cell transplantation

- Sexually active fertile men (with partners that are WOCBP) not using effective birth
control for duration of study and for at least 3 months following combination
treatment.